Gene therapy available for all patients
Socially responsible pricing
We are here for the patient
LentiCure is publicly owned: full subsidiary of Erasmus MC Holding
Open and transparent
Society pays, so it has the right to information
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.
Stay up to date
Podcast: Research is the key – Let’s Talk Business
Tuesday, January 20, 2026
The Prinses Beatrix Spierfonds funds, guides, and stimulates scientific research into muscle diseases, because it knows that scientific research is the only key to making all muscle diseases treatable in the future. Listen to the New Business Radio podcast Let’s Talk Business #634.
Donate to the Spierfonds and make a difference
Tuesday, January 20, 2026
Every day, people with a muscle disease need our help. With your donation, you help make groundbreaking research possible, improve treatments, and give hope to thousands of people in the Netherlands. Discover why your contribution can have such an impact.
We have never been more hopeful
Tuesday, January 20, 2026
Start-up for gene therapy for Pompe disease. With the collaboration between Erasmus MC and the start-up LentiCure, the Prinses Beatrix Spierfonds is taking a new step. The goal is to develop a gene therapy for Pompe disease.